FORMULA BASED ON PEER REVIEWED SCIENTIFIC EVIDENCE
For women with PCOS, clinical research has shown that the ovaries are rich in D-Chiro Inositol.
On the other hand, women without PCOS typically have follicular fluid rich in Myo-Inositol.
But why does this happen?
In women with PCOS, imbalanced insulin levels lead to the conversion of myo-inositol into excessive d-chiro inositol.
This leads to PCOS symptoms related to cycle health: from irregular cycles, through to egg quality.
This also impacts androgen levels and related skin health and weight challenges caused by excess insulin.
The science behind the 40:1 ratio
With that in mind, why would women with PCOS want D-Chiro at all? Haven't we already got enough of it?
Interestingly, studies have shown that supplementing a combination of D-Chiro and Myo Inositol in a 40:1 ratio proves to have significantly better results than either inositol by itself.
This includes studied benefits for:
Ovulation
Regular Cycles
Egg Quality
Metabolism and weight support
The Studies Behind Why Inositol Works (for the nerds 🤓):
🎓[1] Nestler, J.E.; Unfer, V. Reflections on Inositol(s) for PCOS Therapy: Steps toward Success. Gynecol. Endocrinol. 2015, 31, 501–505
🎓[2] Facchinetti, F.; Orrù, B.; Grandi, G.; Unfer, V. Short-Term Effects of M**tformin and Myo-Inositol in Women with Polycystic Ovarian Syndrome (PCOS): A Meta-Analysis of Randomized Clinical Trials. Facchinetti F1, Orrù B2, Grandi G1, Unfer V3. Gynecol. Endocrinol. 2019, 35, 198–206
🎓[3] Laganà, A.S.; Rossetti, P.; Buscema, M.; La Vignera, S.; Condorelli, R.A.; Gullo, G.; Granese, R.; Triolo, O. Metabolism and Ovarian Function in PCOSWomen: ATherapeutic Approach with Inositols. Int. J. Endocrinol. 2016, 2016, 6306410.
🎓[4] Unfer V, Carlomagno G, Papaleo E, Vailati S, Candiani M, Baillargeon JP. Hyperinsulinemia Alters Myoinositol to d-chiroinositol Ratio in the Follicular Fluid of Patients With PCOS. Reprod Sci. 2014;21(7):854-8.
🎓[5] Unfer, V.; Facchinetti, F.; Orrù, B.; Giordani, B.; Nestler, J. Myo-Inositol Effects in Women with PCOS: A Meta-Analysis of Randomized Controlled Trials. Endocr. Connect. 2017, 6, 647–658.
🎓[6] Benelli, E.; Del Ghianda, S.; Di Cosmo, C.; Tonacchera, M. A Combined Therapy with Myo-Inositol and D-Chiro-Inositol Improves Endocrine Parameters and Insulin Resistance in PCOS Young Overweight Women. Int. J. Endocrinol. 2016, 2016, 3204083
🎓[7] Bevilacqua, A.; Carlomagno, G.; Gerli, S.; Oliva, M.M.; Devroey, P.; Lanzone, A.; Soulange, C.; Facchinetti, F.; Di Renzo, G.C.; Bizzarri, M.; et al. Results from the International Consensus Conference on Myo-Inositol and D-Chiro-Inositol in Obstetrics and Gynecology-Assisted Reproduction Technology. Gynecol. Endocrinol. 2015, 31, 441–446.
🎓[8] Colazingari, S.; Treglia, M.; Najjar, R.; Bevilacqua, A. The Combined Therapy Myo-Inositol plus D-Chiro-Inositol, Rather than D-Chiro-Inositol, Is Able to Improve IVF Outcomes: Results froma Randomized Controlled Trial. Arch. Gynecol. Obstet. 2013, 288, 1405–1411.
🎓[9] Ravanos K, Monastra G, Pavlidou T, Goudakou M, Prapas N. Can high levels of D-chiro-inositol in follicular fluid exert detrimental effects on blastocyst quality? European review for medical and pharmacological sciences. 2017;21(23):5491-8.
🎓[10] Dinicola, S.; Chiu, T.T.Y.; Unfer, V.; Carlomagno, G.; Bizzarri, M. The Rationale of the Myo-Inositol and D-Chiro-Inositol Combined Treatment for Polycystic Ovary Syndrome. J. Clin. Pharmacol. 2014, 54, 1079–1092
🎓[11] Bevilacqua, A.; Dragotto, J.; Giuliani, A.; Bizzarri, M. Myo-Inositol and D-Chiro-Inositol (40:1) Reverse
Histological and Functional Features of Polycystic Ovary Syndrome in a Mouse Model. J. Cell. Physiol. 2019,
234, 9387–9398.
🎓[12] Diamanti-Kandarakis, E.; Dunaif, A. Insulin Resistance and the Polycystic Ovary Syndrome Revisited: An Update on Mechanisms and Implications. Endocr. Rev. 2012, 33, 981–1030.
🎓[13] Abdel Hamid AMS, Ismail Madkour WA, Borg TF. Inositol versus M*****min administration in polycystic ovary syndrome patients: a case–control study. Journal of Evidence-Based Women’s Health Journal Society. 2015;5(3). https://journals.lww.com/ebjwh/Fulltext/2015/08000/Inositol_versus_***_administration_in.2.aspx
